Home › Myelofibrosis › Washington
Myelofibrosis clinical trials in Washington
11 studies for Myelofibrosis are looking for participants at sites in Washington.
Cities in Washington
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Washington - Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Fred Hutch Cancer Research, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07357727A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- University of Washington, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07623161Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- University of Washington, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 19, 2026 · NCT07228624Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 20, 2026 · NCT04370301Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- GSK Investigational Site, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06517875A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Fred Hutchinson Cancer Centre, Seattle
- Northwest Medical Specialties, PLLC - Tacoma, Tacoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.